End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Shah, Bijal D.
Bishop, Michael Russell
Oluwole, Olalekan O.
Logan, Aaron
Baer, Maria R.
Donnellan, William Bruce
Carr-O'Dwyer, Kristen Marie
Holmes, Houston
Arellano, Martha Lucia
Ghobadi, Armin
Pagel, John M.
Lin, Yi
Cassaday, Ryan Daniel
Park, Jae Hong
Mardiros, Armen
Shen, Tong
Goyal, Lovely
Vezan, Remus
Jain, Rajul K.
Wierda, William G.
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA
[5] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA
[6] Sarah Cannon Res Inst, Nashville, TN USA
[7] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[8] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[9] Winship Canc Inst, Atlanta, GA USA
[10] Washington Univ, Sch Med, St Louis, MO USA
[11] Siteman Canc Ctr, St Louis, MO USA
[12] Swedish Canc Inst, Seattle, WA USA
[13] Mayo Clin, Rochester, MN USA
[14] Univ Washington, Sch Med, Seattle, WA USA
[15] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[17] Kite, Santa Monica, CA USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7006
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    GWierda, William
    Bishop, Michael R.
    Oluwole, Olalekan
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Castro, Januario E.
    Schiller, Gary J.
    Holmes, Houston
    Abedi, Mehrdad
    Ghobadi, Armin
    Arellano, Martha L.
    Malone, Adriana K.
    Pagel, John M.
    Mardiros, Armen
    Shen, Tong
    Vezan, Remus
    Jain, Rajul K.
    Shah, Bijal D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [2] Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
    Shah, Bijal D.
    Stock, Wendy
    Wierda, William G.
    Oluwole, Olalekan
    Holmes, Houston
    Schiller, Gary J.
    Topp, Max S.
    Kersten, Marie Jose
    Houot, Roch
    Boissel, Nicolas
    Mojadidi, Michelle
    Xue, Allen
    Mardiros, Armen
    Jiang, Yizhou
    Shen, Tong
    Aycock, Jeff S.
    Stout, Shanna
    Wiezorek, Jeffrey S.
    Jain, Rajul
    BLOOD, 2017, 130
  • [3] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
    Shah, Bijal D.
    Bishop, Michael R.
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Holmes, Houston
    Arellano, Martha L.
    Ghobadi, Armin
    Pagel, John M.
    Lin, Yi
    Cassaday, Ryan D.
    Park, Jae H.
    Abedi, Mehrdad
    Castro, Januario E.
    DeAngelo, Daniel J.
    Malone, Adriana K.
    Mawad, Raya
    Schiller, Gary J.
    Rossi, John M.
    Bot, Adrian
    Shen, Tong
    Goyal, Lovely
    Jain, Rajul K.
    Vezan, Remus
    Wierda, William G.
    BLOOD, 2021, 138 (01) : 11 - 22
  • [4] Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron
    Boissel, Nicolas
    Cassaday, Ryan Daniel
    Forcade, Edouard
    Bishop, Michael Russell
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha Lucia
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Dong, Jinghui
    Shen, Tong
    Milletti, Francesca
    Masouleh, Behzad Kharabi
    Houot, Roch
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Topp, M. S.
    Shah, B. D.
    Ghobadi, A.
    Oluwole, O. O.
    Logan, A. C.
    Boissel, N.
    Cassaday, R. D.
    Forcade, E.
    Bishop, M. R.
    Tzachanis, D.
    O'Dwyer, K. M.
    Arellano, M. L.
    Lin, Y.
    Baer, M. R.
    Schiller, G. J.
    Dong, J.
    Shen, T.
    Milletti, F.
    Masouleh, Kharabi B.
    Houot, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 16 - 16
  • [6] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study
    Wang, Michael
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S1 - S1
  • [7] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study
    Wang, Michael L.
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    BLOOD, 2019, 134
  • [8] Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Wierda, William G.
    Bishop, Michael R.
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Castro, Januario E.
    Schiller, Gary J.
    Holmes, Houston
    Abedi, Mehrdad
    Ghobadi, Armin
    Arellano, Martha L.
    Malone, Adriana K.
    Pagel, John M.
    Mardiros, Armen
    Shen, Tong
    Vezan, Remus
    Jain, Rajul K.
    Shah, Bijal D.
    BLOOD, 2018, 132
  • [9] Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Shah, Bijal D.
    Oluwole, Olalekan O.
    Baer, Maria R.
    Bishop, Michael Russell
    Holmes, Houston Eccleston
    Schiller, Gary J.
    Donnellan, William Bruce
    Carr-O'Dwyer, Kristen Marie
    Mardiros, Armen
    Rossi, John M.
    Shen, Tong
    Xue, Allen
    Jain, Rajul K.
    Vezan, Remus
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions
    Shah, Bijal
    Stock, Wendy
    Wierda, William
    Topp, Max
    Kersten, Marie Jose
    Houot, Roch
    Boissel, Nicolas
    Holmes, Houston
    Schiller, Gary
    Mardiros, Armen
    Rossi, John
    Jiang, Yizhou
    Shen, Tong
    Aycock, Jeff
    Stout, Shanna
    Wiezorek, Jeff
    Jain, Rajul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S253 - S253
12345